Effect of Bimagrumab on body composition: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background: Sarcopenia, a condition marked by progressive muscle mass and function decline, presents significant challenges in aging populations and those with chronic illnesses. Current standard treatments such as dietary interventions and exercise programs are often unsustainable. There is increasing interest in pharmacological interventions like bimagrumab, a monoclonal antibody that promotes muscle hypertrophy by inhibiting muscle atrophy ligands. Bimagrumab has shown effectiveness in various conditions, including sarcopenia. Aim: The primary objective of this meta-analysis is to evaluate the impact of bimagrumab treatment on both physical performance and body composition among patients diagnosed with sarcopenia. Materials and methods: This meta-analysis follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We systematically searched PubMed, Ovid/Medline, Web of Science, and the Cochrane Library databases up to June 2024 using appropriate Medical Subject Headings (MeSH) terms and keywords related to bimagrumab and sarcopenia. Eligible studies were randomized controlled trials (RCTs) that assessed the effects of bimagrumab on physical performance (e.g., muscle strength, gait speed, six-minute walk distance) and body composition (e.g., muscle volume, fat-free body mass, fat body mass) in patients with sarcopenia. Data extraction was independently performed by two reviewers using a standardized form, with discrepancies resolved through discussion or consultation with a third reviewer. Results: From an initial search yielding 46 records, we screened titles, abstracts, and full texts to include seven RCTs in our meta-analysis. Bimagrumab treatment significantly increased thigh muscle volume (mean difference [MD] 5.29%, 95% confidence interval [CI] 4.08% to 6.50%, P < 0.001; moderate heterogeneity χ2 = 6.41, I2 = 38%, P = 0.17) and fat-free body mass (MD 1.90 kg, 95% CI 1.57 kg to 2.23 kg, P < 0.001; moderate heterogeneity χ2 = 8.60, I2 = 30%, P = 0.20), while decreasing fat body mass compared to placebo (MD − 4.55 kg, 95% CI − 5.08 kg to − 4.01 kg, P < 0.001; substantial heterogeneity χ2 = 27.44, I2 = 89%, P < 0.001). However, no significant improvement was observed in muscle strength or physical performance measures such as gait speed and six-minute walk distance with bimagrumab treatment, except among participants with slower baseline walking speeds or distances. Discussion and conclusion: This meta-analysis provides valuable insights into the effects of bimagrumab on sarcopenic patients, highlighting its significant improvements in body composition parameters but limited impact on functional outcomes. The observed heterogeneity in outcomes across studies underscores the need for cautious interpretation, considering variations in study populations, treatment durations, and outcome assessments. While bimagrumab shows promise as a safe pharmacological intervention for enhancing muscle mass and reducing fat mass in sarcopenia, its minimal effects on muscle strength and broader physical performance suggest potential limitations in translating body composition improvements into functional gains. Further research is needed to clarify its long-term efficacy, optimal dosing regimens, and potential benefits for specific subgroups of sarcopenic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Meta-analyses confirm robust effects on body composition, but variable functional outcomes, highlighting the importance of patient selection and concomitant exercise/nutritional strategies [65].”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [65]
The cited source says what the claim attributes to it.
In the citing paper
“A recent systematic review and meta-analysis confirmed these dual effects of bimagrumab on increasing muscle mass and reducing fat mass in humans [182].”
From Effects of Skeletal Muscle Hypertrophy on Fat Mass and Glucose Homeostasis in Humans and Animals: A Narrative Review with Systematic Literature Search (2025) · cites this paper as [182]
In the citing paper
“Phase 1 and 2 trials showed that bimagrumab treatment significantly increased FFM and was also effective in reducing FM [154].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [154]
In the citing paper
“Meta-analyses confirm robust effects on body composition, but variable functional outcomes, highlighting the importance of patient selection and concomitant exercise/nutritional strategies [65].”
From Muscle loss and GLP-1R agonists use (2025) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 2×
“…mean differences The x-axis is in % (for thigh muscle volume) or Kg (for lean body mass and fat body mass) ranging between 2.5% to 35% depending on the study population with higher rates in elderly populations and depending on the method of investigation and diagnostic criteria utilized [1, 20–22].”
InfluentialLiberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2009.06.006 · Cited by 10,578
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Mutations in myostatin ( GDF8 ) in Double-Muscled Belgian Blue and Piedmontese Cattle
Kambadur, R., Sharma, M., Smith, T. P. L., & Bass, J. J. (1997) · Genome Research · doi:10.1101/gr.7.9.910 · Cited by 1,204 · cited 1×
“It has been shown that both humans and animals with genetic mutations that reduce or eliminate myostatin have increased muscle mass, but are otherwise healthy [13, 14].”
Epidemiology of sarcopenia: Prevalence, risk factors, and consequences
Yuan, S., & Larsson, S. C. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155533 · Cited by 1,114
Sarcopenia: A Contemporary Health Problem among Older Adult Populations
Papadopoulou, S. (2020) · Nutrients · doi:10.3390/nu12051293 · Cited by 588 · cited 1×
“…sarcopenia include physical exercise programs such as aerobic exercise, resistance training, high-intensity interval training and whole-body vibration therapy as well as dietary modifications including high-protein nutritional supplements, supplementation with vitamin D and anti-oxidant agents [3].”
Pathogenesis and Management of Sarcopenia
Dhillon, R. J. S., & Hasni, S. (2017) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2016.08.002 · Cited by 574
Effects of Exercise and Aging on Skeletal Muscle
Distefano, G., & Goodpaster, B. H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029785 · Cited by 479 · cited 1×
“Secondly, age-related alterations in muscle composition, such as increased intramuscular fat and fibrosis, may impede the translation of increased mass into enhanced function [24].”
Patel, H. P., Syddall, H. E., Jameson, K., Robinson, S., Denison, H., Roberts, H. C., Edwards, M., Dennison, E., Cooper, C., & Aihie Sayer, A. (2013) · Age and Ageing · doi:10.1093/ageing/afs197 · Cited by 384 · cited 1×
“…mean differences The x-axis is in % (for thigh muscle volume) or Kg (for lean body mass and fat body mass) ranging between 2.5% to 35% depending on the study population with higher rates in elderly populations and depending on the method of investigation and diagnostic criteria utilized [1, 20–22].”
InfluentialMyostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial
Becker, C., Lord, S. R., Studenski, S. A., Warden, S. J., Fielding, R. A., Recknor, C. P., Hochberg, M. C., Ferrari, S. L., Blain, H., Binder, E. F., et al. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00298-3 · Cited by 381
Sarcopenia and mortality among a population‐based sample of community‐dwelling older adults
Brown, J. C., Harhay, M. O., & Harhay, M. N. (2016) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12073 · Cited by 354 · cited 1×
“…mean differences The x-axis is in % (for thigh muscle volume) or Kg (for lean body mass and fat body mass) ranging between 2.5% to 35% depending on the study population with higher rates in elderly populations and depending on the method of investigation and diagnostic criteria utilized [1, 20–22].”
InfluentialHeymsfield, S. B., Coleman, L. A., Miller, R., Rooks, D. S., Laurent, D., Petricoul, O., Praestgaard, J., Swan, T., Wade, T., Perry, R. G., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.33457 · Cited by 338
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 3×
“Its effects are thought to result from the attenuation of negative regulators of muscle mass, such as myostatin [6, 7].”
Dobrescu, A., Nussbaumer-Streit, B., Klerings, I., Wagner, G., Persad, E., Sommer, I., Herkner, H., & Gartlehner, G. (2021) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.04.012 · Cited by 265 · cited 1×
“Indeed, limiting systematic reviews to English-language publications has been already shown to exert minimal influence on the effect estimates and overall conclusions drawn from them [16].”
Rooks, D., Praestgaard, J., Hariry, S., Laurent, D., Petricoul, O., Perry, R. G., Lach‐Trifilieff, E., & Roubenoff, R. (2017) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14927 · Cited by 244
Rooks, D., Swan, T., Goswami, B., Filosa, L. A., Bunte, O., Panchaud, N., Coleman, L. A., Miller, R. R., Garcia Garayoa, E., Praestgaard, J., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.20836 · Cited by 177 · cited 10×
“Although a minimally, but significant, increase was noted by Rooks et al. [8] at different time points during the study period, no changes were seen in the other two other studies [10, 19].”
InfluentialA single ascending‐dose study of muscle regulator ace‐031 in healthy volunteers
Attie, K. M., Borgstein, N. G., Yang, Y., Condon, C. H., Wilson, D. M., Pearsall, A. E., Kumar, R., Willins, D. A., Seehra, J. S., & Sherman, M. L. (2013) · Muscle & Nerve · doi:10.1002/mus.23539 · Cited by 176 · cited 1×
“…have been proposed and investigated in pre-clinical and clinical studies including the use of anti-ligand, primarily against myostatin such as domagrozumab [29–31], the use of soluble activin type IIB receptor blockers, namely ACE-031 [32], and use of receptor antagonists such as bimagrumab (Fig.”
Kim, H., Hirano, H., Edahiro, A., Ohara, Y., Watanabe, Y., Kojima, N., Kim, M., Hosoi, E., Yoshida, Y., Yoshida, H., et al. (2016) · Geriatrics & Gerontology International · doi:10.1111/ggi.12723 · Cited by 163
Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T. B., Huang, Y., Eckersdorff, M., Rafique, A., Mastaitis, J., et al. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0060-8 · Cited by 143
Hanna, M. G., Badrising, U. A., Benveniste, O., Lloyd, T. E., Needham, M., Chinoy, H., Aoki, M., Machado, P. M., Liang, C., Reardon, K. A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30200-5 · Cited by 138
Tezze, C., Sandri, M., & Tessari, P. (2023) · Nutrients · doi:10.3390/nu15184073 · Cited by 129
Polkey, M. I., Praestgaard, J., Berwick, A., Franssen, F. M. E., Singh, D., Steiner, M. C., Casaburi, R., Tillmann, H.-C., Lach-Trifilieff, E., Roubenoff, R., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201802-0286oc · Cited by 111 · cited 4×
“Two studies used two doses of 30 mg/kg bimagrumab (at baseline and 8 weeks) [7, 11].”
InfluentialRehabilitation Nutrition for Injury Recovery of Athletes: The Role of Macronutrient Intake
Papadopoulou, S. K. (2020) · Nutrients · doi:10.3390/nu12082449 · Cited by 111
Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophy
Rooks, D. S., Laurent, D., Praestgaard, J., Rasmussen, S., Bartlett, M., & Tankó, L. B. (2017) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12205 · Cited by 90 · cited 9×
“[8, 10, 12, 18, 19] Although not included in the meta-analysis because of unit incompatibility of the results, Rooks, Laurent et al. [8] also identified an increase in fat-free body mass and 3).”
InfluentialBimagrumab improves body composition and insulin sensitivity in insulin‐resistant individuals
Garito, T., Roubenoff, R., Hompesch, M., Morrow, L., Gomez, K., Rooks, D., Meyers, C., Buchsbaum, M. S., Neelakantham, S., Swan, T., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13042 · Cited by 88 · cited 1×
“Similar patterns of improvement in fat-free body mass and total body fat mass have been demonstrated in another clinical trial involving sixteen participants with a mean body-mass index of 29.3 kg/m2 and insulin resistance after receiving a single dose of bimagrumab therapy [33].”
InfluentialLiang, Y., Zhang, N., Wang, M., Liu, Y., Ma, L., Wang, Q., Yang, Q., Liu, X., Zhou, F., & Wei, Y. (2023) · Nutrients · doi:10.3390/nu16010132 · Cited by 71
Principles of the activin receptor signaling pathway and its inhibition
Lodberg, A. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.04.001 · Cited by 62 · cited 2×
“…mitogen-activated protein kinases (MAPK) activation, suppression of mothers against decapentaplegic (Smad) and forkhead box transcription factors (FoxO) activation and phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapam-ycin (mTOR) pathway inhibition occur [28].”
Obstacles to the Early Diagnosis and Management of Sarcopenia: Current Perspectives
Ooi, H., & Welch, C. (2024) · Clinical Interventions in Aging · doi:10.2147/cia.s438144 · Cited by 62 · cited 1×
“Lastly, inadequate dosages or durations of treatment, treatment compliance, may limit the therapeutic potential of anabolic agents in sarcopenic patients [27].”
Liu, J., Zhu, Y., Tan, J. K., Ismail, A. H., Ibrahim, R. B., & Hassan, N. H. (2023) · Nutrients · doi:10.3390/nu15204335 · Cited by 59
Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy
Saitoh, M., Ishida, J., Ebner, N., Anker, S. D., Springer, J., & von Haehling, S. (2017) · JCSM Clinical Reports · doi:10.17987/jcsm-cr.v2i1.37 · Cited by 57 · cited 1×
“Therefore, with several clinical studies yielding neutral or disappointing results, there is growing interest in developing novel pharmacotherapeutic approaches for the management of sarcopenia [4, 5].”
Rooks, D., Petricoul, O., Praestgaard, J., Bartlett, M., Laurent, D., & Roubenoff, R. (2020) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12639 · Cited by 54 · cited 7×
“Also, another study evaluating the efficiency and safety of bimagrumab therapy on elderly participants with obesity has illustrated effectiveness and safety on 24 participants [18].”
InfluentialBhattacharya, I., Pawlak, S., Marraffino, S., Christensen, J., Sherlock, S. P., Alvey, C., Morris, C., Arkin, S., & Binks, M. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.386 · Cited by 50
Hofbauer, L. C., Witvrouw, R., Varga, Z., Shiota, N., Cremer, M., Tanko, L. B., Rooks, D., Auberson, L. Z., Arkuszewski, M., Fretault, N., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00084-2 · Cited by 38 · cited 8×
“[8, 10, 12, 18, 19] Although not included in the meta-analysis because of unit incompatibility of the results, Rooks, Laurent et al. [8] also identified an increase in fat-free body mass and 3).”
InfluentialGrowth hormone secretagogues: history, mechanism of action, and clinical development
Ishida, J., Saitoh, M., Ebner, N., Springer, J., Anker, S. D., & von Haehling, S. (2020) · JCSM Rapid Communications · doi:10.1002/rco2.9 · Cited by 32
Cited by
Stefanakis, K., Kokkorakis, M., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156057 · Cited by 142
Skeletal muscle and MASLD: Mechanistic and clinical insights
Marjot, T., Armstrong, M. J., & Stine, J. G. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000711 · Cited by 83
“…in sarcopenic obesity, where it serves to both increase muscle mass (with improvements in glucose disposal) and simultaneously decrease fat mass. [174,175] Preclinical work has also started to explore the role of myostatin inhibition alongside GLP-1RA therapy to preserve muscle mass [176]…”
Biomarkers of aging: from molecules and surrogates to physiology and function
Furrer, R., & Handschin, C. (2025) · Physiological Reviews · doi:10.1152/physrev.00045.2024 · Cited by 74
Sarcopenic obesity and weight loss-induced muscle mass loss
Caturano, A., Amaro, A., Berra, C., & Conte, C. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001131 · Cited by 73
Muscle loss and GLP-1R agonists use
Rossi, G., Bucciarelli, L., Mananguite, C.-L., Giovarelli, M., & Fiorina, P. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02611-2 · Cited by 31
Metadata
- Authors
- Kanbay, M., Siriopol, D., Copur, S., Hasbal, N. B., Güldan, M., Kalantar-Zadeh, K., Garfias-Veitl, T., & von Haehling, S.
- Affiliations
- Koç University (TR)
- Ştefan cel Mare University of Suceava (RO)
- Venue
- Aging Clinical and Experimental Research
- Published
- 2024-09-09
- Volume
- 36
- Issue
- 1
- Pages
- 185-185
- ISSN
- 1594-0667 (ISSN-L)
- 1720-8319
- PMC
- PMC11385021
- OpenAlex
- W4402349387
- Cited by
- 45
- References
- 35
- Citations by year
- 2026: 21 · 2025: 23 · 2024: 1
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Aging Clinical and Experimental Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Funders
- Herzzentrum Göttingen
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Keywords
- bimagrumab, sarcopenia, body composition, muscle hypertrophy, thigh muscle volume, fat-free mass, fat mass, physical performance, muscle strength, walking speed, 6-minute walk distance, monoclonal antibodies, aging, chronic disease, adverse events, cost-effectiveness, quality of life
- MeSH terms
- Body Composition, Humans, Randomized Controlled Trials as Topic, Muscle Strength, Sarcopenia, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.